Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences beat expectations on adjusted EPS while revenue came in line with consensus, as its second fiscal quarter of 2026 results reported August 4, 2026 showed revenue up 6.2% year over year to roughly $192.4 million. On the bottom line, adjusted EPS of $0.73 topped the $0.65 estimate (+13%), while revenue of $192.4 million was in line with the $191.1 million estimate (+0.7%). Profitability remained high on a gross basis, with gross profit of about $148.2 million translating to a gross margin near 77%, and operating income of roughly $4.3 million for an operating margin around 2.2%. Net income was about $4.7 million, a swing from net income of -$4.8 million a year ago. The quarter also generated operating cash flow of about $57.5 million. For the next period, consensus calls for EPS of $0.76 on revenue of $181.8 million.